Article

CRISPR/Cas9-mediated gene editing induces neurological recovery in an A53T-SNCA overexpression rat model of Parkinson’s disease

2020-08-27

Abstract excerpt

To date, no publicly available disease-modifying therapy for Parkinson’s disease has been developed. This can be partly attributed to the absence of techniques for in vivo deletion of the SNCA gene (encoding α-synuclein), which is one of the key players in Parkinson’s disease pathology. In particular, A53T-mutated SNCA (A53T-SNCA) is one of the most studied familial pathologic mutations in Parkinson’s disease. He...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: ee0fe6e6-b0e2-57dd-b75e-4fe76490568a
DOI: 10.1101/2020.08.27.269522

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

CRISPR/Cas9-mediated gene editing induces neurological recovery in an A53T-SNCA overexpression rat model of Parkinson’s diseaseDOI 10.1101/2020.08.27.269522Read

CRISPR-Cas9 Gene Editing Protects from the A53T-SNCA Overexpression-Induced Pathology of Parkinson's Disease In Vivo.Semantic proximity Read

Inactive S. aureus Cas9 downregulates alpha-synuclein and reduces mtDNA damage and oxidative stress levels in human stem cell model of Parkinson’s diseaseSemantic proximity Read

Nuclease-dead S. <i>aureus</i> Cas9 downregulates alpha-synuclein and reduces mtDNA damage and oxidative stress levels in patient-derived stem cell model of Parkinson’s diseaseSemantic proximity Read

<i>SNCA</i> -targeted epigenome therapy for Parkinson’s disease alleviates pathological and behavioral perturbations in a mouse modelSemantic proximity Read

Phenotypic analysis of the CRISPR-engineered G51D α-synuclein ratSemantic proximity Read

Finding the 'Guilty' Gene Variant of Sporadic Parkinson's Disease Via CRISPR/Cas9.Semantic proximity Read

Global Effects of a PD Risk-SNP at the Alpha-Synuclein LocusSemantic proximity Read

Neuronal-type-specific epigenome editing to decrease SNCA expression: Implications for precision medicine in synucleinopathiesSemantic proximity Read

CRISPR System: A High-throughput Toolbox for Research and Treatment of Parkinson's Disease.Semantic proximity Read

Generation of gene-corrected isogenic controls from Parkinson's disease patient iPSC lines carrying the pathogenic SNCA p.A53T variantSemantic proximity Read

Advancements in CRISPR-Based Therapies for Genetic Modulation in Neurodegenerative Disorders.Semantic proximity Read

Robust nuclease-dead S. aureus dCas9-mediated alpha-synuclein knockdown in substantia nigra in a humanized mouse model of Parkinson’s diseaseSemantic proximity Read